Investigating Factors Influencing the Long-Term Outcome of Teriparatide Treatment on the Risk of Hip Fracture. Is sequential treatment essential?

Clicks: 10
ID: 339242
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #145 of 148 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 148 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
INTRODUCTION: Teriparatide (TPTD) is an anabolic therapy for severe osteoporosis. Clinical trials have shown its efficacy in reducing vertebral and non-vertebral fractures, data on hip fracture prevention in real-world settings and the impact of sequential antiresorptive (AR) therapy remain limited. METHODS: We conducted a retrospective cohort study using the Hungarian National Health Insurance Database, which covers the entire population (~9.7 million). Patients with osteoporosis who received TPTD between 2010 and 2023, with treatment initiated by January 1, 2022. Hip fractures were tracked from day 180 after TPTD initiation for up to five years. Adherence was assessed via medication possession ratio. Post-TPTD AR therapy (bisphosphonate or denosumab) and the timing of its initiation were evaluated as factors influencing hip fracture risk. Poisson regression models were applied, adjusting for demographics, prior fractures, and healthcare utilization. RESULTS: Among 8,893 eligible patients, 574 hip fractures occurred during follow-up. High adherence was associated with reduced hip fracture risk by 20% (p<0.05). The number of fractures prior to treatment was also associated with fracture risk, increasing it by 11% (p<0.05). Delayed AR initiation was closely related to a proportional increase in risk, which grew proportionally with the time elapsed between the two treatments. In a cohort of patients exhibiting high adherence, deferring AR treatment for over 90 days post-TPTD therapy was associated with an increase of 19% in hip fracture risk when subsequent treatment involved bisphosphonates, and a 31% increase when denosumab was utilized as the follow-up therapy. CONCLUSIONS: The efficacy of teriparatide treatment was associated with patient adherence and the number of prior fractures. Neglecting to initiate AR treatment following teriparatide therapy, or starting it late, was strongly linked to an increased risk of hip fractures. Our findings provide real-world data supporting timely initiation of AR therapy post-TPTD for sustained fracture prevention.
Reference Key
openalex_W7225561493 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal journal of bone and mineral research : the official journal of the american society for bone and mineral research
Year 2026
DOI
10.1093/jbmr/zjag156
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.